H.C. Wainwright raised the firm’s price target on Unicycive Therapeutics (UNCY) to $22 from $9 and keeps a Buy rating on the shares. The believes the company’s regulatory overhang has been revolved after its Type A meeting with the FDA. Unicycive plans to file a response to the complete response letter by year-end and expects a decision in the first half of 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY: